dr. hershman on misconceptions with the tailorx trial in hr /her2- breast cancer
Published 4 years ago • 545 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
2:09
dr. hershman on drug adherence in breast cancer
-
1:11
dr. hershman on adherence to longer hormonal therapy
-
2:23
an overview of the neomonarch trial in hr /her2- breast cancer
-
1:42
dr. hamilton on the her2climb trial in metastatic her2 breast cancer
-
1:45
dr. sramila aithal describes the herceptin adjuvant (hera) trial for her2-positive breast cancer
-
6:54
key clinical trials investigating immunotherapy in her2 and hr breast cancer
-
2:14
management of premenopausal hr /her2- breast cancer with micro-metastasis
-
3:20
dr. hurvitz on eliminating anthracyclines in her2 breast cancer treatment
-
4:48
oncotype dx testing and the tailorx trial
-
1:33
ongoing trial of abemaciclib and pembrolizumab in hr /her2-negative breast cancer
-
0:54
treatment de-escalation in premenopausal patients with hr /her2- breast cancer and micro-metastasis
-
0:35
key challenge associated with the management of hr /her2- breast cancer
-
1:16:56
navigating the integration of trop2-targeted therapy in tnbc and hr , her2- breast cancer
-
33:11
recent updates in hr-positive/her2-negative early breast cancer: a deep dive into understanding t...
-
3:49
unmet needs in r/r her2 metastatic breast cancer
-
5:06
safety outcomes in the phase iii monarche trial of abemaciclib et in hr , her2- breast cancer
-
1:00
dr. hershman on the equivalency of biosimilars and biologics
-
2:54
groundbreaking tailorx trial results on women with breast cancer
-
1:17
comment: phase 3 study shows her2 therapy clinically meaningful for metastatic breast cancer pts